Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cosentyx special drug use-results survey in pediatric psoriasis and psoriatic arthritis
jRCT2031210589Completed
- Sponsor
- Novartis
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of secukinumab in plaque psoriasis, psoriatic arthritis (PsA) and pustular psoriasis, sponsored by Novartis. Primary endpoint: Incidence of serious adverse events. Started Feb 2022; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)pustular psoriasis
Beyond the preview
Go deeper on jRCT2031210589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210589.